April 2024
1. ABRAHAO R, Brunson A, Ruddy KJ, Li Q, et al
   Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study.
   Br J Cancer. 2024;130:1166-1175.
   

   >> Share

   
   February 2024
2. LITTLE MP, Mai JZ, Fang M, Chernyavskiy P, et al
   Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based dataset.
   Br J Cancer. 2024 Feb 29. doi: 10.1038/s41416-024-02629.
   

   >> Share

   
   June 2023
3. BEDICS G, Egyed B, Kotmayer L, Benard-Slagter A, et al
   PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia.
   Br J Cancer. 2023 Jun 21. doi: 10.1038/s41416-023-02309.
   

   >> Share

   
   November 2022
4. SUNGUC C, Hawkins MM, Winter DL, Dudley IM, et al
   Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study.
   Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02016.
   

   >> Share

   
   October 2022
5. BUTLER EN, Zhou CK, Curry M, McMenamin U, et al
   Testosterone therapy and cancer risks among men in the SEER-Medicare linked database.
   Br J Cancer. 2022 Oct 28. pii: 10.1038/s41416-022-02019.
   

   >> Share

   
   August 2022
6. EKBERG S, Crowther M, Harrysson S, Jerkeman M, et al
   Patient trajectories after diagnosis of diffuse large B-cell lymphoma-a multistate modelling approach to estimate the chance of lasting remission.
   Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01931.
   

   >> Share

   
   May 2022
7. NOBLE RA, Thomas H, Zhao Y, Herendi L, et al
   Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma.
   Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01848.
   

   >> Share

   
   November 2021
8. AITAMER M, Akil H, Vignoles C, Branchaud M, et al
   CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles.
   Br J Cancer. 2021 Nov 6. pii: 10.1038/s41416-021-01611.
   

   >> Share

   
   October 2021
9. DURAND-PANTEIX S, Monteil J, Sage M, Garot A, et al
   Preclinical study of (212)Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma.
   Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01585.
   

   >> Share

   
   
10. HOUNSOME L, Eyre TA, Ireland R, Hodson A, et al
    Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.
    Br J Cancer. 2021 Oct 5. pii: 10.1038/s41416-021-01525.
    

    >> Share

    
    August 2021
11. SMITH MJ, Fernandez MAL, Belot A, Quartagno M, et al
    Investigating the inequalities in route to diagnosis amongst patients with diffuse large B-cell or follicular lymphoma in England.
    Br J Cancer. 2021 Aug 13. pii: 10.1038/s41416-021-01523.
    

    >> Share

    
    May 2021
12. CAI J, Tian X, Ma S, Zhong L, et al
    A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01434.
    

    >> Share

    
    December 2020
13. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share